These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16990079)

  • 41. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
    Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
    AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia.
    Saunders E; Ferdinand K; Yellen LG; Tonkon MJ; Krug-Gourley S; Poland M
    J Natl Med Assoc; 2000 Jul; 92(7):319-26. PubMed ID: 10946527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):349-54. PubMed ID: 22900989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia.
    Lee WJ; Lee WL; Tang YJ; Liang KW; Chien YH; Tsou SS; Sheu WH
    Clin Chim Acta; 2008 Apr; 390(1-2):49-55. PubMed ID: 18201563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study.
    Nakagawa T; Kobayashi T; Awata N; Sato S; Reiber JH; Nakajima H; Toyama YN; Hiraoka H; Kato O; Kirino M; Kobayashi T; Takeda Y; Yachiku K; Iida M; Itoh T; Shibata N
    Int J Cardiol; 2004 Oct; 97(1):107-14. PubMed ID: 15336816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
    Strauss WE; Lapsley D; Gaziano JM
    Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
    Sebestjen M; Boh M; Keber I
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):999-1003. PubMed ID: 12635468
    [TBL] [Abstract][Full Text] [Related]  

  • 50. APPROACH-J study: design, rationale, and baseline data of the affirmation primary prevention with pravastatin in reduction of occlusive atherosclerotic complications in hypercholesterolemia--Japan study.
    Teramoto T; Kitagawa Y; Daida H;
    J Atheroscler Thromb; 2011; 18(12):1054-61. PubMed ID: 21921414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.
    Dangas G; Badimon JJ; Smith DA; Unger AH; Levine D; Shao JH; Meraj P; Fier C; Fallon JT; Ambrose JA
    J Am Coll Cardiol; 1999 Apr; 33(5):1294-304. PubMed ID: 10193730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
    Hunninghake DB; Knopp RH; Schonfeld G; Goldberg AC; Brown WV; Schaefer EJ; Margolis S; Dobs AS; Mellies MJ; Insull W
    Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pravastatin potentiates increases in serum adiponectin concentration in dyslipidemic patients receiving thiazolidinedione: the DOLPHIN study.
    Nezu U; Tsunoda S; Yoshimura H; Kuwabara T; Tomura S; Seki Y; Kaneshiro M; Kamiyama H; Harada Y; Shigematsu E; Aoki K; Yamakawa T; Ohshige K; Natsumeda Y; Terauchi Y
    J Atheroscler Thromb; 2010 Oct; 17(10):1063-9. PubMed ID: 20702974
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of a HMG-CoA reductase inhibitor combined with hormone replacement therapy on lipid metabolism in Japanese women with hypoestrogenic lipidemia: a multicenter double-blind controlled prospective study.
    Ohta H; Komukai S; Sugimoto I; Fuyuki T; Makita K; Takamatsu K; Horiguchi F; Nozawa S
    Maturitas; 1998 Jun; 29(2):163-71. PubMed ID: 9651906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between adiponectin and leptin, and blood lipids in hyperlipidemia patients treated with red yeast rice.
    Lee CY; Jan MS; Yu MC; Lin CC; Wei JC; Shih HC
    Forsch Komplementmed; 2013; 20(3):197-203. PubMed ID: 23860021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation.
    Fieseler HG; Armstrong VW; Wieland E; Thiery J; Schütz E; Walli AK; Seidel D
    Clin Chim Acta; 1991 Dec; 204(1-3):291-300. PubMed ID: 1840246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
    Carlsson CM; Papcke-Benson K; Carnes M; McBride PE; Stein JH
    Drugs Aging; 2002; 19(10):793-805. PubMed ID: 12390056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.